{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:50:41Z","timestamp":1776916241691,"version":"3.51.2"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Mol and Cell Biol"],"DOI":"10.1186\/s12860-024-00528-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:17:44Z","timestamp":1737469064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BRAF regulates circPSD3\/miR-526b\/RAP2A axis to hinder papillary thyroid carcinoma progression"],"prefix":"10.1186","volume":"26","author":[{"given":"Chuang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lemei","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"10387","key":"528_CR1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"DW Chen","year":"2023","unstructured":"Chen DW, et al. Thyroid cancer. Lancet. 2023;401(10387):1531\u201344.","journal-title":"Lancet"},{"key":"528_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-0716-2505-7_2","volume":"2534","author":"I Abe","year":"2022","unstructured":"Abe I, Lam AK. Assessment of papillary thyroid carcinoma with ultrasound examination. Methods Mol Biol. 2022;2534:17\u201328.","journal-title":"Methods Mol Biol"},{"key":"528_CR3","doi-asserted-by":"publisher","first-page":"p9989757","DOI":"10.1155\/2021\/9989757","volume":"2021","author":"W Chatchomchuan","year":"2021","unstructured":"Chatchomchuan W, et al. Recurrence factors and characteristic trends of papillary thyroid Cancer over three decades. Int J Endocrinol. 2021;2021:9989757.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"528_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic T, et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid. 2019;29(3):311\u201321.","journal-title":"Thyroid"},{"issue":"4","key":"528_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/21541264.2015.1071301","volume":"6","author":"C Huang","year":"2015","unstructured":"Huang C, Shan G. What happens at or after transcription: insights into circRNA biogenesis and function. Transcription. 2015;6(4):61\u20134.","journal-title":"Transcription"},{"key":"528_CR6","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.drup.2023.100937","volume":"67","author":"X Guo","year":"2023","unstructured":"Guo X, et al. Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance. Drug Resist Updat. 2023;67:100937.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"528_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"528_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei M, et al. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.","journal-title":"Mol Cancer"},{"issue":"10","key":"528_CR9","doi-asserted-by":"publisher","first-page":"153217","DOI":"10.1016\/j.prp.2020.153217","volume":"216","author":"S Borran","year":"2020","unstructured":"Borran S, et al. Circular RNAs: New players in thyroid cancer. Pathol Res Pract. 2020;216(10):153217.","journal-title":"Pathol Res Pract"},{"key":"528_CR10","doi-asserted-by":"publisher","first-page":"115217","DOI":"10.1016\/j.biopha.2023.115217","volume":"165","author":"Z He","year":"2023","unstructured":"He Z, Zhu Q. Circular RNAs: emerging roles and new insights in human cancers. Biomed Pharmacother. 2023;165:115217.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"528_CR11","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1002\/ctm2.565","volume":"11","author":"J Zhou","year":"2021","unstructured":"Zhou J, et al. Hsa_circ_0001666 suppresses the progression of colorectal cancer through the miR-576-5p\/PCDH10 axis. Clin Transl Med. 2021;11(11):e565.","journal-title":"Clin Transl Med"},{"key":"528_CR12","doi-asserted-by":"crossref","unstructured":"Zhao F et al. circFADS2 regulates lung cancer cells proliferation and invasion via acting as a sponge of miR-498. Biosci Rep. 2018;38(4).","DOI":"10.1042\/BSR20180570"},{"issue":"12","key":"528_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41419-020-03276-1","volume":"11","author":"G Huang","year":"2020","unstructured":"Huang G, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p\/RTKN2 axis and activating Wnt\/\u03b2-catenin pathway. Cell Death Dis. 2020;11(12):1065.","journal-title":"Cell Death Dis"},{"issue":"1","key":"528_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13000-021-01153-9","volume":"16","author":"C Li","year":"2021","unstructured":"Li C, et al. CircRNA NRIP1 promotes papillary thyroid carcinoma progression by sponging mir-195-5p and modulating the P38 MAPK and JAK\/STAT pathways. Diagn Pathol. 2021;16(1):93.","journal-title":"Diagn Pathol"},{"issue":"4","key":"528_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","volume":"176","author":"JN Vo","year":"2019","unstructured":"Vo JN, et al. The Landscape of circular RNA in Cancer. Cell. 2019;176(4):869\u2013e88113.","journal-title":"Cell"},{"key":"528_CR16","doi-asserted-by":"publisher","first-page":"p5084631","DOI":"10.1155\/2022\/5084631","volume":"2022","author":"X Xie","year":"2022","unstructured":"Xie X, et al. Downregulation of circular RNA circPSD3 promotes metastasis by modulating FBXW7 expression in clear cell renal cell carcinoma. J Oncol. 2022;2022:5084631.","journal-title":"J Oncol"},{"issue":"1","key":"528_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-023-01882-z","volume":"22","author":"L Xu","year":"2023","unstructured":"Xu L, et al. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma. Mol Cancer. 2023;22(1):174.","journal-title":"Mol Cancer"},{"issue":"3","key":"528_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/10799893.2021.1910706","volume":"42","author":"J Zhu","year":"2022","unstructured":"Zhu J, et al. circ-PSD3 promoted proliferation and invasion of papillary thyroid cancer cells via regulating the miR-7-5p\/METTL7B axis. J Recept Signal Transduct Res. 2022;42(3):251\u201360.","journal-title":"J Recept Signal Transduct Res"},{"key":"528_CR19","doi-asserted-by":"publisher","first-page":"118622","DOI":"10.1016\/j.lfs.2020.118622","volume":"264","author":"Z Li","year":"2021","unstructured":"Li Z, et al. Circ_PSD3 promotes the progression of papillary thyroid carcinoma via the miR-637\/HEMGN axis. Life Sci. 2021;264:118622.","journal-title":"Life Sci"},{"issue":"6","key":"528_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1530\/ERC-14-0147","volume":"21","author":"MH Kim","year":"2014","unstructured":"Kim MH, et al. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression. Endocr Relat Cancer. 2014;21(6):891\u2013902.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"528_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2741\/4359","volume":"20","author":"DD Li","year":"2015","unstructured":"Li DD, et al. The role of BRAF in the pathogenesis of thyroid carcinoma. Front Biosci (Landmark Ed). 2015;20(7):1068\u201378.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"528_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","volume":"246","author":"E Kebebew","year":"2007","unstructured":"Kebebew E, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466\u201370. discussion 470-1.","journal-title":"Ann Surg"},{"issue":"5","key":"528_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.21037\/gs.2016.09.09","volume":"5","author":"A Czarniecka","year":"2016","unstructured":"Czarniecka A, Oczko-Wojciechowska M, Barczy\u0144ski M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 2016;5(5):495\u2013505.","journal-title":"Gland Surg"},{"issue":"3","key":"528_CR24","doi-asserted-by":"publisher","first-page":"e0170287","DOI":"10.1371\/journal.pone.0170287","volume":"12","author":"N Peng","year":"2017","unstructured":"Peng N, et al. Microarray profiling of circular RNAs in human papillary thyroid carcinoma. PLoS ONE. 2017;12(3):e0170287.","journal-title":"PLoS ONE"},{"issue":"1","key":"528_CR25","doi-asserted-by":"publisher","first-page":"12674","DOI":"10.1038\/s41598-022-16207-1","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, et al. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas. Sci Rep. 2022;12(1):12674.","journal-title":"Sci Rep"},{"issue":"7483","key":"528_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature12986","volume":"505","author":"Y Tay","year":"2014","unstructured":"Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344\u201352.","journal-title":"Nature"},{"issue":"8","key":"528_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41419-021-04033-8","volume":"12","author":"KB Chen","year":"2021","unstructured":"Chen KB, et al. miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1. Cell Death Dis. 2021;12(8):748.","journal-title":"Cell Death Dis"},{"issue":"12","key":"528_CR28","first-page":"2679","volume":"9","author":"Z Fang","year":"2019","unstructured":"Fang Z, et al. YY1 promotes colorectal cancer proliferation through the miR-526b-3p\/E2F1 axis. Am J Cancer Res. 2019;9(12):2679\u201392.","journal-title":"Am J Cancer Res"},{"key":"528_CR29","doi-asserted-by":"publisher","first-page":"696269","DOI":"10.3389\/fonc.2021.696269","volume":"11","author":"JH Liu","year":"2021","unstructured":"Liu JH, et al. MiR-526b-3p attenuates breast cancer stem cell properties and chemoresistance by targeting HIF-2\u03b1\/Notch signaling. Front Oncol. 2021;11:696269.","journal-title":"Front Oncol"},{"key":"528_CR30","doi-asserted-by":"publisher","first-page":"594528","DOI":"10.3389\/fcell.2020.594528","volume":"8","author":"F Wu","year":"2020","unstructured":"Wu F, et al. The suppression of miR-199a-3p by promoter methylation contributes to papillary thyroid carcinoma aggressiveness by targeting RAP2a and DNMT3a. Front Cell Dev Biol. 2020;8:594528.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"528_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/ERC-12-0086","volume":"19","author":"X Dong","year":"2012","unstructured":"Dong X, et al. RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer. 2012;19(4):575\u201388.","journal-title":"Endocr Relat Cancer"},{"key":"528_CR32","doi-asserted-by":"crossref","unstructured":"Attia AS et al. Association of BRAF(V600E) mutation with the aggressive behavior of papillary thyroid microcarcinoma: a Meta-analysis of 33 studies. Int J Mol Sci. 2022;23(24).","DOI":"10.3390\/ijms232415626"},{"issue":"3","key":"528_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.yexmp.2011.01.008","volume":"90","author":"H Erdem","year":"2011","unstructured":"Erdem H, G\u00fcndogdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011;90(3):312\u20137.","journal-title":"Exp Mol Pathol"},{"issue":"9","key":"528_CR34","first-page":"4446","volume":"13","author":"JY Kim","year":"2023","unstructured":"Kim JY, et al. Integrative analysis of circular RNA regulatory network in papillary thyroid carcinoma. Am J Cancer Res. 2023;13(9):4446\u201365.","journal-title":"Am J Cancer Res"},{"key":"528_CR35","doi-asserted-by":"crossref","unstructured":"Zhu G et al. CircRNA: a novel potential strategy to treat thyroid cancer (review). Int J Mol Med. 2021;48(5).","DOI":"10.3892\/ijmm.2021.5034"},{"issue":"1","key":"528_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41420-021-00798-1","volume":"8","author":"D Zhang","year":"2022","unstructured":"Zhang D, et al. CircRNA circTIAM1 promotes papillary thyroid cancer progression through the miR-646\/HNRNPA1 signaling pathway. Cell Death Discov. 2022;8(1):21.","journal-title":"Cell Death Discov"},{"issue":"6","key":"528_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1507\/endocrj.EJ20-0726","volume":"68","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Silencing circRNA protein kinase C iota (circ-PRKCI) suppresses cell progression and glycolysis of human papillary thyroid cancer through circ-PRKCI\/miR-335\/E2F3 ceRNA axis. Endocr J. 2021;68(6):713\u201327.","journal-title":"Endocr J"},{"key":"528_CR38","doi-asserted-by":"publisher","first-page":"p3977189","DOI":"10.1155\/2021\/3977189","volume":"2021","author":"YM Jiang","year":"2021","unstructured":"Jiang YM, et al. CircLDLR promotes papillary thyroid carcinoma tumorigenicity by regulating miR-637\/LMO4 Axis. Dis Markers. 2021;2021:3977189.","journal-title":"Dis Markers"},{"issue":"1","key":"528_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/2211536607666180827111633","volume":"8","author":"M Tafrihi","year":"2019","unstructured":"Tafrihi M, Hasheminasab E. MiRNAs: Biology, biogenesis, their web-based tools, and databases. Microrna. 2019;8(1):4\u201327.","journal-title":"Microrna"},{"issue":"4","key":"528_CR40","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/brv.12428","volume":"93","author":"SP Kabekkodu","year":"2018","unstructured":"Kabekkodu SP, et al. Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc. 2018;93(4):1955\u201386.","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"10","key":"528_CR41","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jmedgenet-2015-103334","volume":"52","author":"X Qi","year":"2015","unstructured":"Qi X, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710\u20138.","journal-title":"J Med Genet"},{"key":"528_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.omtn.2021.01.007","volume":"23","author":"FT Bu","year":"2021","unstructured":"Bu FT, Circular RNA, et al. circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p\/Smad7 axis. Mol Ther Nucleic Acids. 2021;23:847\u201362.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"528_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12935-021-02055-y","volume":"21","author":"Q Lin","year":"2021","unstructured":"Lin Q, et al. NCK1-AS1 promotes the progression of melanoma by accelerating cell proliferation and migration via targeting miR-526b-5p\/ADAM15 axis. Cancer Cell Int. 2021;21(1):367.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"528_CR44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10528-021-10182-4","volume":"60","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. LncRNA LOXL1-AS1 facilitates the oncogenic character in cervical cancer by the miR-526b-5p \/LYPLA1 Axis. Biochem Genet. 2022;60(4):1298\u2013312.","journal-title":"Biochem Genet"},{"key":"528_CR45","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3389\/fonc.2020.01250","volume":"10","author":"P Liu","year":"2020","unstructured":"Liu P, et al. Circ0085539 promotes osteosarcoma progression by suppressing miR-526b-5p and PHLDA1 Axis. Front Oncol. 2020;10:1250.","journal-title":"Front Oncol"},{"key":"528_CR46","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.2147\/CMAR.S263985","volume":"12","author":"Q Kong","year":"2020","unstructured":"Kong Q, et al. CircRNA circUGGT2 contributes to Hepatocellular Carcinoma Development via Regulation of the miR-526b-5p\/RAB1A Axis. Cancer Manag Res. 2020;12:10229\u201341.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"528_CR47","doi-asserted-by":"publisher","first-page":"e00812","DOI":"10.1002\/prp2.812","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Circ_0001821 knockdown suppresses growth, metastasis, and TAX resistance of non-small-cell lung cancer cells by regulating the miR-526b-5p\/GRK5 axis. Pharmacol Res Perspect. 2021;9(4):e00812.","journal-title":"Pharmacol Res Perspect"},{"issue":"18","key":"528_CR48","first-page":"9541","volume":"24","author":"JQ Liu","year":"2020","unstructured":"Liu JQ, et al. Abnormal expression of Rap2A as a prognostic marker for human breast cancer. Eur Rev Med Pharmacol Sci. 2020;24(18):9541\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"528_CR49","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cellsig.2015.02.026","volume":"27","author":"JX Wu","year":"2015","unstructured":"Wu JX, et al. Rap2a is a novel target gene of p53 and regulates cancer cell migration and invasion. Cell Signal. 2015;27(6):1198\u2013207.","journal-title":"Cell Signal"},{"issue":"1","key":"528_CR50","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1038\/s41598-017-06162-7","volume":"7","author":"JX Wu","year":"2017","unstructured":"Wu JX, et al. Rap2a serves as a potential prognostic indicator of renal cell carcinoma and promotes its migration and invasion through up-regulating p-Akt. Sci Rep. 2017;7(1):6623.","journal-title":"Sci Rep"},{"issue":"1","key":"528_CR51","first-page":"350","volume":"19","author":"J Zhang","year":"2020","unstructured":"Zhang J, et al. Knockdown of RAP2A gene expression suppresses cisplatin resistance in gastric cancer cells. Oncol Lett. 2020;19(1):350\u20138.","journal-title":"Oncol Lett"},{"key":"528_CR52","doi-asserted-by":"publisher","first-page":"979840","DOI":"10.4061\/2011\/979840","volume":"2011","author":"I Prabakaran","year":"2011","unstructured":"Prabakaran I, et al. Rap2A is upregulated in invasive cells dissected from follicular thyroid Cancer. J Thyroid Res. 2011;2011:979840.","journal-title":"J Thyroid Res"},{"issue":"5","key":"528_CR53","first-page":"469","volume":"34","author":"JY Ng","year":"2019","unstructured":"Ng JY, Lu CT, Lam AK. BRAF mutation: current and future clinical pathological applications in colorectal carcinoma. Histol Histopathol. 2019;34(5):469\u201377.","journal-title":"Histol Histopathol"},{"issue":"1","key":"528_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCO.0000000000000797","volume":"34","author":"RS Scheffel","year":"2022","unstructured":"Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022;34(1):9\u201318.","journal-title":"Curr Opin Oncol"},{"key":"528_CR55","doi-asserted-by":"publisher","first-page":"p9959649","DOI":"10.1155\/2022\/9959649","volume":"2022","author":"X Wei","year":"2022","unstructured":"Wei X, et al. Risk and prognostic factors for BRAF(V600E) mutations in papillary thyroid carcinoma. Biomed Res Int. 2022;2022:p9959649.","journal-title":"Biomed Res Int"},{"issue":"1","key":"528_CR56","doi-asserted-by":"publisher","first-page":"12604","DOI":"10.1038\/s41598-023-39747-6","volume":"13","author":"EA Agyekum","year":"2023","unstructured":"Agyekum EA, et al. Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography. Sci Rep. 2023;13(1):12604.","journal-title":"Sci Rep"},{"issue":"22","key":"528_CR57","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1200\/JCO.2015.61.4016","volume":"33","author":"M Xing","year":"2015","unstructured":"Xing M, Mutation BRAF. Thyroid Cancer recurrence. J Clin Oncol. 2015;33(22):2482\u20133.","journal-title":"J Clin Oncol"},{"issue":"12","key":"528_CR58","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.21037\/gs-22-701","volume":"11","author":"M Zhang","year":"2022","unstructured":"Zhang M, et al. Combined expression of the BRAF(V600E) mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study. Gland Surg. 2022;11(12):1908\u201323.","journal-title":"Gland Surg"},{"key":"528_CR59","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.12659\/MSM.904928","volume":"23","author":"D Zhou","year":"2017","unstructured":"Zhou D, Li Z, Bai X. BRAFV600E and RET\/PTC promote Proliferation and Migration of Papillary thyroid carcinoma cells in Vitro by Regulating Nuclear Factor-\u03baB. Med Sci Monit. 2017;23:5321\u20139.","journal-title":"Med Sci Monit"}],"container-title":["BMC Molecular and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-024-00528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12860-024-00528-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-024-00528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:58:20Z","timestamp":1737511100000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmolcellbiol.biomedcentral.com\/articles\/10.1186\/s12860-024-00528-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1186\/s12860-024-00528-2","relation":{},"ISSN":["2661-8850"],"issn-type":[{"value":"2661-8850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided their written, voluntarily informed consent. All procedures related to humans and animals were carried out in accordance with the guidelines outlined in the Helsinki Declaration, and this study was approved by the Ethics Committee of the Henan Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}